Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
4 papers
A single ibogaine treatment reduced opioid withdrawal symptoms and achieved opioid cessation or sustained reduced use in dependent individuals as measured over 12 months. Ibogaine's legal availability in New Zealand may offer improved outcomes where legislation supports treatment providers to work closely with other health professionals.
Ibogaine is a psychoactive chemical from a West African shrub that some clinics use to help people stop using opioids or stimulants. Small studies, animal research, and many personal reports say a single high dose can cut opioid withdrawal and reduce cravings. For example, one study found 50% of participants…
Project Twenty21 collected real-world data from people in the UK who sought prescribed medicinal cannabis. Data at treatment start were available for 2,833 patients and 1,410 had 3-month follow-up for anxiety, chronic pain or PTSD. On average, patients reported improvements in condition-specific symptoms and in general health and quality of…
This review says that low (sub-anesthetic) doses of ketamine can produce strong short-term pain relief by blocking NMDA receptors and by boosting descending pain-inhibiting pathways. It is well documented to help with pain around the time of surgery and is linked to less long-term postoperative pain and lower opioid use.…
